News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MannKind (MNKD) Responds To Hurricane Harvey Devastation With Afrezza Donation



9/7/2017 8:57:59 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
- Donation of inhalable insulin provides support for those living with diabetes.

WESTLAKE VILLAGE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company’s support for Hurricane Harvey victims with a donation of Afrezza® (insulin human) Inhalation Powder. The donation will be shipped this week to Insulin for Life USA, Inc., a not-for-profit entity whose purpose is to aid those living with diabetes by supplying life-saving insulin and other disease management supplies in times of need. Insulin for Life USA, Inc., The American Diabetes Association, and JDRF have partnered to ensure that donated diabetic supplies get to shelters and county health leaders in the affected areas as soon as possible.

“In times of crisis, many of us rely on our good health to help us get to better days,” said Michael Castagna, CEO of MannKind Corporation. “Among the millions of residents impacted by Hurricane Harvey are people who must manage their diabetes to maintain good health – but are separated by circumstance from their supplies. Extending a helping hand is consistent with our company’s values, and simply the right thing to do.”

Available through prescription only, Afrezza® is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. MannKind has authorized over 27,000 cartridges of insulin to be donated to Insulin for Life USA. For more information, including important safety information, on Afrezza®, visit www.afrezza.com.

“When it comes to rebuilding a life following a major event like Hurricane Harvey, things rarely go according to schedule,” said Castagna. “We hope that our support provides some relief to those in need during such a challenging time.”

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact: Rose Alinaya SVP, Investor Relations 818-661-5000 ir@mannkindcorp.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES